Inclusion Criteria:

- Signed informed consent

- Biopsy proven neuroendocrine tumor, neuroblastoma, medulloblastoma, or other
somatostatin receptor positive tumor

- Off Sandostatin (octreotide acetate)-long acting release (LAR) > 4 weeks and off
immediate release (subcutaneous) for 12 hrs prior to 68Ga-DOTATOC PET-CT

- Karnofsky performance status or Lansky Play Scale status of >= 50 (or Eastern
Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)

- Subject is male; or is a female who is either pre-menarchal, surgically sterile (has
had a documented bilateral oophorectomy and/or documented hysterectomy),
postmenopausal (> 1 years without menses), non-lactating, or of childbearing
potential for whom a serum pregnancy test (with the results known prior to
investigational product administration) is negative; a negative serum pregnancy test
will be required for all female subjects with child bearing potential; if a false
pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be
consulted to determine if she is/is capable of becoming pregnant

- No therapy other than Sandostatin since last Octreoscan + diagnostic CT

- Fresh frozen (recommended) or paraffin fixed (required) specimen of primary or
metastases available for ribonucleic acid (RNA) and immunohistochemistry (IHC)

Exclusion Criteria:

- Pregnancy or breast feeding

- Surgical resection, chemotherapy, radiation therapy, or biologic therapy since last
Octreoscan + CT; continuation of the same dose of Sandostatin-LAR or subcutaneous
Sandostatin is allowed

- Medical condition uncontrolled by treatment making completion of study unlikely

- Weight more than 400 pounds (subjects who weigh more than 400 pounds will not be able
to fit inside the imaging machines)

- Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,
etc.)

- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the investigator, may significantly interfere
with study compliance